Guardian Pharmacy Services, INC. (GRDN) — SEC Filings

Overview

Guardian Pharmacy Services, INC. (GRDN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Mar 26, 2026: Guardian Pharmacy Services, Inc. filed a DEFA14A on March 26, 2026, which is additional definitive proxy soliciting materials. This filing indicates the company is likely preparing for an upcoming shareholder vote or seeking shareholder approval for a specific corporate action. For investors, this m

Sentiment Summary

Across 24 filings, the sentiment breakdown is: 1 bullish, 22 neutral, 1 mixed. The dominant filing sentiment for Guardian Pharmacy Services, INC. is neutral.

Filing Type Overview

Guardian Pharmacy Services, INC. (GRDN) has filed 1 DEFA14A, 10 8-K, 4 10-Q, 1 10-K, 6 SC 13G, 2 S-1/A with the SEC between Aug 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (24)

• Guardian Pharmacy Files DEFA14A: Shareholder Vote Imminent — DEFA14A · Mar 26, 2026
  Guardian Pharmacy Services, Inc. filed a DEFA14A on March 26, 2026, which is additional definitive proxy soliciting materials. This filing indicates the company
• Guardian Pharmacy Enters Material Definitive Agreement — 8-K · Mar 23, 2026
  Guardian Pharmacy Services, Inc. filed an 8-K on March 23, 2026, reporting an "Entry into a Material Definitive Agreement" under Item 1.01, effective March 18,
• GRDN Swings to Profit on Soaring Revenue, Cost Cuts — 10-Q · Nov 10, 2025 Risk: medium
  Guardian Pharmacy Services, Inc. (GRDN) reported a significant turnaround in its financial performance for the nine months ended September 30, 2025, with revenu
• Guardian Pharmacy Services Files 8-K — 8-K · Oct 14, 2025 Risk: low
  Guardian Pharmacy Services, Inc. filed an 8-K on October 14, 2025, reporting "Other Events." The filing does not contain specific details about the nature of th
• Guardian Pharmacy Services (GRDN) Files Current Report — 8-K · Sep 18, 2025 Risk: low
  Guardian Pharmacy Services, Inc. (GRDN) reported on September 18, 2025, that its Class A Common Stock is listed on the New York Stock Exchange. The company, inc
• Guardian Pharmacy Debuts Post-IPO Results, Details Acquisitions — 10-Q · Aug 11, 2025 Risk: medium
  Guardian Pharmacy Services, Inc. (GRDN) reported its first post-IPO financial results for the three and six months ended June 30, 2025, following its Corporate
• Guardian Pharmacy Services Files 8-K — 8-K · Jun 18, 2025 Risk: low
  Guardian Pharmacy Services, Inc. filed an 8-K on June 18, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, form
• Guardian Pharmacy Services Files 8-K — 8-K · May 20, 2025 Risk: low
  Guardian Pharmacy Services, Inc. filed an 8-K on May 20, 2025, reporting an entry into a material definitive agreement and filing financial statements and exhib
• Guardian Pharmacy Services Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: medium
  Guardian Pharmacy Services, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details net income per share for Class A and Class B common sto
• Guardian Pharmacy Services Announces Director Changes & Compensation Updates — 8-K · Mar 28, 2025 Risk: low
  Guardian Pharmacy Services, Inc. announced on March 24, 2025, changes in its board of directors and executive compensation arrangements. The filing details the
• Guardian Pharmacy Services Files 2024 10-K Post-IPO — 10-K · Mar 26, 2025 Risk: medium
  Guardian Pharmacy Services, Inc. filed its 2024 10-K on March 26, 2025, reporting financial results for the fiscal year ending December 31, 2024. The filing ind
• Guardian Pharmacy Services Files 8-K — 8-K · Mar 3, 2025 Risk: low
  Guardian Pharmacy Services, Inc. filed an 8-K on March 3, 2025, reporting on its results of operations and financial condition. The filing also includes Regulat
• Guardian Pharmacy Services Announces Director Changes & Compensation Updates — 8-K · Feb 11, 2025 Risk: low
  Guardian Pharmacy Services, Inc. announced on February 5, 2025, changes in its board of directors and executive compensation arrangements. The filing details th
• Guardian Pharmacy Services Files 8-K on Material Agreement — 8-K · Dec 20, 2024 Risk: medium
  On December 20, 2024, Guardian Pharmacy Services, Inc. filed an 8-K report detailing a material definitive agreement. The filing also indicates the creation of
• SC 13G Filing — SC 13G · Dec 6, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• Guardian Pharmacy Services Files Q3 10-Q Post-IPO — 10-Q · Nov 12, 2024 Risk: medium
  Guardian Pharmacy Services, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance following its initial public
• SC 13G Filing — SC 13G · Nov 8, 2024
• SC 13G Filing — SC 13G · Oct 8, 2024
• Guardian Pharmacy Services Reports Material Definitive Agreement — 8-K · Sep 30, 2024 Risk: medium
  Guardian Pharmacy Services, Inc. filed an 8-K on September 25, 2024, reporting several material events. These include entering into a material definitive agreem
• Guardian Pharmacy Services Files S-1/A Amendment — S-1/A · Sep 16, 2024 Risk: medium
  Guardian Pharmacy Services, Inc. filed an S-1/A amendment on September 16, 2024, for its initial public offering. The company, incorporated in Delaware, is base
• Guardian Pharmacy Services Files S-1/A Amendment — S-1/A · Aug 22, 2024 Risk: medium
  Guardian Pharmacy Services, Inc. filed an S-1/A amendment on August 22, 2024, to its registration statement. The company, incorporated in Delaware, is a retail

Risk Profile

Risk Assessment: Of GRDN's 16 recent filings, 0 were flagged as high-risk, 9 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Guardian Pharmacy Services, INC.'s most recent 10-Q filing (Nov 10, 2025):

• Revenue: $1,051,069 thousand
• Net Income: $27,693 thousand
• EPS: $0.46
• Cash Position: $36,487 thousand
• Operating Margin: 3.99%
• Total Assets: $390,037 thousand

Key Executives

• Atlanta
• Fred P. Burke

Industry Context

Guardian Pharmacy Services operates in the specialized pharmacy services sector, focusing on long-term health care facilities (LTCFs). This niche is characterized by a growing elderly population requiring ongoing care and a demand for integrated pharmacy solutions that improve medication adherence and reduce overall healthcare costs. The competitive landscape includes national pharmacy chains, independent pharmacies, and other specialized LTCF providers, necessitating a focus on technology-enabled services and strong client relationships.

Top Tags

material-agreement (4) · 10-Q (3) · IPO (3) · 8-K (2) · Pharmacy Services (2) · financials (2) · pharmacy (2) · governance (2) · executive-compensation (2) · board-changes (2)

Key Numbers

• Total Revenues: $1,051,069 thousand — Increased from $889,840 thousand in 2024 for the nine months ended September 30, 2025, representing 18.1% growth.
• Net Income: $27,693 thousand — Swung from a net loss of $82,874 thousand in 2024 for the nine months ended September 30, 2025.
• Selling, General, and Administrative Expenses: $165,277 thousand — Decreased significantly from $256,942 thousand in 2024 for the nine months ended September 30, 2025.
• Operating Income: $41,939 thousand — Improved from an operating loss of $79,675 thousand in 2024 for the nine months ended September 30, 2025.
• Cash and Cash Equivalents: $36,487 thousand — Increased from $4,660 thousand at December 31, 2024, as of September 30, 2025.
• Net Cash Provided by Operating Activities: $65,655 thousand — Increased from $35,623 thousand in 2024 for the nine months ended September 30, 2025.
• Total Assets: $390,037 thousand — Increased from $320,810 thousand at December 31, 2024, as of September 30, 2025.
• Basic Net Income Per Share: $0.46 — Improved from a basic net loss per share of $2.00 in 2024 for the nine months ended September 30, 2025.
• Conformed Period of Report: 2025-06-30 — The financial reporting period covered by this 10-Q.
• Filed As Of Date: 2025-08-11 — The date the 10-Q was officially filed with the SEC.
• SEC File Number: 001-42284 — Unique identifier for the company's SEC filings.
• Public Document Count: 49 — Number of documents included in the filing.
• Standard Industrial Classification (SIC): 5912 — Indicates the company operates in 'RETAIL-DRUG STORES AND PROPRIETARY STORES'.
• IRS Employer Identification No.: 87-3627139 — Tax identification number
• Reporting Period: Q1 2025 — First quarter financial results are detailed.

Frequently Asked Questions